'Neointimal hyperplasia' diaporamas de présentation

SVS Clinical Research Priorities Hemodialysis Access

SVS Clinical Research Priorities Hemodialysis Access. Thomas S. Huber, MD, PhD Professor and Chief Division of Vascular Surgery University of Florida College of Medicine. Patient Counts by Treatment for ESRD. Prevalent Counts by Modality. 65 %. 30%. 5%. 5-year Mortality by Incident Access.

627 views • 52 slides

SVS Clinical Research Priorities Hemodialysis Access

SVS Clinical Research Priorities Hemodialysis Access. Thomas S. Huber, MD, PhD Professor and Chief Division of Vascular Surgery University of Florida College of Medicine. Patient Counts by Treatment for ESRD. Prevalent Counts by Modality. 65 %. 30%. 5%. 5-year Mortality by Incident Access.

697 views • 52 slides

Salvatore Tarantini U.O. Chirurgia Vascolare Rimini Direttore Dr Massimiliano Gessaroli

883 views • 26 slides

Radiation for restenosis: the dark side of arteries

Radiation for restenosis: the dark side of arteries. hot. Robert S Schwartz MD Professor of Medicine Mayo Clinic Rochester, MN. Figure 1. Stimulation of neointima within an irradiated artery. Figure 2. Minimal neointimal neoplasia post stent placement. External beam radiation.

340 views • 24 slides

Oral Cilostazol Prevents Restenosis And Repeat Revascularization After Percutaneous Coronary Stenting: A Meta-Analysis Of 15 Randomized Trials And 4897 Patients. G. Biondi-Zoccai, 1 C. Moretti, 1 M. Lotrionte, 2 P. Agostoni, 3 F. Sciuto, 1

256 views • 18 slides